Patients and medical groups have launched an ad campaign in opposition to President Donald Trump’s drug-pricing proposal. The coalition argues that the proposals put “patients’ lives at risk.” Groups such as the American Cancer Society and the American Medical Association are backing the efforts. (STAT)

Apple is in discussions with private Medicare plans to make the Apple Watch more affordable for individuals over 65. If insurers can subsidize the high cost, seniors may be able to benefit from the device’s health features, such as fall detection and heart monitoring. No deals have been made official yet. (CNBC)

The Food and Drug Administration has updated its draft guidance on rare diseases. Changes were made in response to feedback received after the first draft was released in 2015. Updated areas include the natural history studies section, the addition of a section on the evaluation of safety questions, and more information on historical controls. (Endpoints)

Lexicon Pharmaceuticals’ diabetes pill is being considered for approval by the FDA. The pill belongs to the SGLT-2 inhibitor class which is known for a severe side effect, diabetic ketoacidosis (DKA). As of now, other SGLT-2 treatments are only approved for type 2 diabetes due to this side effect. (Bloomberg)

The MM&M Podcast is launching soon. In this teaser, MM&M editors Marc Iskowitz and Larry Dobrow introduce themselves and tell listeners what they can expect to hear in this biweekly look at the world of healthcare marketing. (MM&M)